SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ____________________  FORM 10-Q ____________________  [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934  For the quarterly period ended June 30, 2008  [  ] TRANSITION REPORT UNDER SECTION 13 OR 15 ( d ) OF THE EXCHANGE ACT  For the transition period from ____________ to____________  Commission File No. 000-49655   LIPIDVIRO TECH, INC. (Exact name of Registrant as specified in its charter)  Nevada87-0678927(State or Other Jurisdiction of(I.R.S. Employer Identification No.)incorporation or organization)  1338 S. Foothill Drive, #126 Salt Lake City, Utah  84108 (Address of Principal Executive Offices)  (801) 583-9900 (Registrants telephone number, including area code)  N/A (Former name, former address and former fiscal year, if changed since last report)  Indicate by check mark whether the Registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the Exchange Act) during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]  Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.  (Check one):  Large accelerated filer [  ]      Accelerated filer [  ]       Non-accelerated filer [  ]      Smaller reporting company [X]  Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]   1    APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS  Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.  Not applicable.  APPLICABLE ONLY TO CORPORATE ISSUERS  Indicate the number of shares outstanding of each of the Registrants classes of common stock, as of the latest practicable date:  August 13, 2008 - 18,274,525 shares of common stock.  PART I   Item 1.  Financial Statements  The Financial Statements of the Registrant required to be filed with this 10-Q Quarterly Report were prepared by management and commence below, together with related notes. In the opinion of management, the Financial Statements fairly present the financial condition of the Registrant.      2           LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) JUNE 30, 2008 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  3       TABLE OF CONTENTS  PAGE  — Unaudited Condensed Consolidated Balance Sheets, June 30, 2008 and December 31, 2007 5   — Unaudited Condensed Consolidated Statements of Operations, for the three months and six months ended June 30, 2008 and 2007 and for the period from inception on May 6, 2003 through June 30, 2008 6  — Unaudited Condensed Consolidated Statements of Cash Flows, for the six months ended June 30, 2008 and 2007 and for the period from inception on May 6, 2003 through June 30, 2008 7    Notes to Unaudited Condensed Consolidated Financial Statements 9 - 12  4


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS  ASSETS June 30,
2008December 31, 2007CURRENT ASSETS:Cash$25$46Total Current Assets2546PROPERTY AND EQUIPMENT, net373747OTHER ASSETS:Definite-life intangible assets34,63734,637Goodwill290,317290,317TOTAL ASSETS$325,352$325,747LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)CURRENT LIABILITIES:Accounts payable$314,435$275,364Related party loans730,779686,124Total Current Liabilities1,045,214961,488LONG-TERM LIABILITIES:Related party accrued interest82,48067,562Related party note payable600,000600,000Total Liabilities1,727,6941,629,050STOCKHOLDERS EQUITY (DEFICIT):Common Stock, $.001 par value, 150,000,000 shares authorized, 18,274,525
shares issued and outstanding18,27518,275Capital in excess of par value3,891,0203,770,672Deficit accumulated during the development stage(5,311,637)(5,092,250)Total Stockholders Equity (Deficit)(1,402,342)(1,303,303)TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)$325,352$325,747  The accompanying notes are an integral part of these financial statements.


5


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  For the Three Months Ended
June 30,For the Six Months Ended
June 30,For the Period From Inception on May 6, 2003, through June 30,20082007200820072008REVENUE$-$-$-$-$-OPERATING EXPENSES:Consulting608-608306,500564,269Employee Compensation-40,31013,43780,621322,598Other General and    administrative39,88735,88569,01865,893472,281Research and development52,97267,715105,944135,4312,403,173Total Operating Expenses93,467143,910189,007588,4453,762,321OPERATING LOSS(93,467)(143,910)(189,007)(588,445)(3,762,321)OTHER INCOME (EXPENSES):Interest Income----23Foreign currency transaction
Gain (loss)5(12)(101)(28)(278)Related party interest expense(15,339)(160,908)(30,279)(219,977)(1,549,061)Total Other Income (Expense)(15,334)(160,920)(30,380)(220,005)(1,549,316)LOSS BEFORE INCOME TAX PROVISION(108,801)(304,830)(219,387)(808,450)(5,311,637)PROVISION FOR INCOME TAXES-----NET INCOME (LOSS)$(108,801)$(304,830)$(219,387)$(808,450)$(5,311,637)BASIC AND DILUTED LOSS PER SHARE$(0.01)$(0.02)$(0.01)$(0.05)WEIGHTED AVERAGE SHARES OUTSTANDING18,247,44217,941,18318,231,81717,779,996  The accompanying notes are an integral part of these financial statements.


6


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  For the Six Months Ended
June 30,For the Period From Inception On May 6, 2003 through
June 30,200820072008CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)$(219,387)$(808,450)$(5,311,637)Adjustments to reconcile net income (loss) to net cash used by operating activities:Depreciation3743683,302Expense costs related to unsuccessful financing
Transaction--31,900Imputed interest expense--42,377Noncash expenses paid by a shareholder--6,900Noncash expenses paid by issuance of common stock-189,2781,346,919Noncash services paid by issuance of common stock83,625396,7841,232,851Noncash services paid by grant of warrants35,243102,4281,460,695Net (increase) decrease in operating assets:Retainer-10,000-Net increase (decrease) in operating liabilities:Accounts payable39,0715,190313,430Related party loans - interest15,36115,82378,035Related party accrued interest14,91814,87682,480Net Cash (Used) by Operating Activities(30,795)(73,703)(712,748)CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for property and equipment--(3,675)Payments for definite-life intangible assets-(300)(33,632)Payments for goodwill--(269,006)Net Cash (Used) by Investing Activities-(300)(306,313)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from related party loans29,29464,545661,443Payments on related party loans-(4,500)(8,700)Proceeds from capital contributions1,48015,03434,133Proceeds from common stock issuances--293,700Proceeds from sale of warrants--38,510Net Cash Provided by Financing Activities30,77475,0791,019,086  (Continued)


7


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued) For the Six Months Ended
June 30,For the Period From Inception On May 6, 2003 through
June 30,200820072008NET INCREASE (DECREASE) IN CASH(21)1,07625CASH AT BEGINNING OF PERIOD46236-CASH AT END OF PERIOD$25$1,312$25SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:Interest$-$-$-Income Taxes$-$-$-SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:Definite-life intangible asset fees accrued in accounts payable$-$-$1,005Deferred financing costs paid  through issuance of common stock$-$-$31,900Common stock repurchased through issuance of $600,000 note payable and $1 paid by a shareholder$-$-$600,001Common stock issued to purchase minority interest$-$-$21,311   The accompanying notes are an integral part of these financial statements.


8


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 1  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  The accompanying financial statements have been prepared by the Company in accordance with Article 8 of U.S. Securities and Exchange Commission Regulation S-X.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at June 30, 2008 and 2007 and for the periods then ended have been made.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2007 audited financial statements.  The results of operations for the periods ended June 30, 2008 and 2007 are not necessarily indicative of the operating results for the full year.  NOTE 2  GOING CONCERN  The Companys financial statements have been presented on the basis that they are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  At June 30, 2008, the Company had incurred losses since inception, had not yet generated any revenues, and had current liabilities in excess of current assets.  These factors create an uncertainty about the Companys ability to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of common stock.  There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations.  The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.  NOTE 3  PENDING SALE OF RESEARCH ASSETS  On January 3, 2008, for consideration of $100 the Company granted a 60-day option to AcquiSci, Inc. (a New Jersey corporation) to purchase the Companys research subject to the terms of a Purchase Agreement.  The Purchase Agreement calls for AcquiSci, Inc., its shareholders, and their related entities to return all their Company stock and warrants (expected to be 911,793 shares of common stock, 570,000 Class A warrants, and 560,000 Class B warrants), release the Company from all existing debts owed to them (totaling $284,719 as of June 30, 2008), and pay $1 in exchange for all of the Companys research including all the Companys pending patent applications.  In January 2008, AcquiSci, Inc. exercised its option but the Purchase Agreement has not yet closed.  NOTE 4  RELATED PARTY TRANSACTIONS  Related Party Loans  During the six months ended June 30, 2008, shareholders or entities related to them loaned $29,294 to the Company.  In April 2008, the Company started accruing interest at 8% per annum on related party loans that previously bore no interest.  At June 30, 2008, the Company owes a total of $730,779 to the related parties with $541,064 of the loans due when funds are available and the other $189,715 of the loans were due October 1, 2007, were in default as of June 30, 2008, and are expected to be paid subsequently through the disposition of the Companys research (See Note 3).  During the six months ended June 30, 2008 and 2007, the Company accrued interest expense on related party loans totaling $15,361 and $15,823, respectively.  Note Payable  During the six months ended June 30, 2008 and 2007, interest expense on the note payable amounted to $14,918 and $14,876, respectively.  Capital Contributions  During the six months ended June 30, 2008, a shareholder of the Company contributed cash and made payments on behalf of the Company totaling $1,480.


9


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 5  PROPERTY AND EQUIPMENT  Estimated Useful LivesJune 30, 2008Office equipment5 years$433Website5 years3,2423,675Less accumulated depreciation(3,302)Net Property and Equipment$373  Depreciation expense for the six months ended June 30, 2008 and 2007 was $374 and $368, respectively.  NOTE 6  COMMON STOCK, OPTIONS, AND WARRANTS  Warrant Expiration  All of the Companys warrants expired unexercised on June 30, 2008.  Warrant Vesting  Of the 42,083 warrants unvested at December 31, 2007, 14,583 Class A warrants and 25,000 Class B warrants vested during the six months ended June 30, 2008.  The remaining 2,500 Class B warrants expired unvested.  Share-Based Payment Disclosures - During the six months ended June 30, 2008 and 2007, share-based payments resulted in expenses of $118,868 and $688,490, respectively.  A summary of warrant activity as of June 30, 2008 and changes during the six months then ended is presented below:  WarrantsSharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic ValueOutstanding at December 31, 200728,555,000$1.06Granted--Exercised--Forfeited--Expired(28,555,000)1.06Outstanding at June 30, 2008-$--$-Exercisable at June 30, 2008-$--$-  A summary of the status of the non-vested shares as of June 30, 2008 and changes during the six months then ended is presented below:  Non-vested SharesSharesWeighted-Average Grant-Date Fair ValueNon-vested at December 31, 200768,750$1.32Vested(62,500)1.34Non-vested at June 30, 20086,250$1.10  As of June 30, 2008, there was $6,875 of total unrecognized expense related to non-vested share-based payments.  That cost is expected to be recognized over a weighted-average period of 0.1 years.  The total fair value of shares vested during the six months ended June 30, 2008 was $83,625.  NOTE 7  FOREIGN CURRENCY TRANSACTION  During the six months ended June 30, 2008, the Company recorded a foreign currency transaction loss of $101 due to the change in the exchange rate.


10


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 8  INCOME TAXES  At June 30, 2008, the Company has net operating loss carryovers of approximately $453,000 available to offset future taxable income and expiring beginning in 2023 through 2028.  Due to a change in control of the Company in January 2008, the net operating loss carryovers will be subject to an annual limitation of approximately $19,800.  The income tax provision differs from the amounts that would be obtained by applying federal and state statutory income tax rates to loss before income tax provision as follows: For the Six Months Ended June 30,For the Period From Inception on May 6, 2003 Through June 30, 200820082007Loss before income tax provision$(219,387)$(808,450)$(5,311,637)Expected combined federal and state income tax rate20.0%20.0%20.0%Expected income tax expense (benefit) at statutory rates(43,877)(161,690)(1,062,327)Federal benefit of state taxes1,6456,06339,837Tax effect of:Change in control limitation163,568-163,568Meals and entertainment-2082Change in valuation allowance(121,336)155,607858,840Net income tax expense (benefit)$-$-$-  The Companys deferred tax assets, deferred tax liabilities, and valuation allowance are as follows:  June 30, 2008Deferred tax assets:Research and development equipment$756Share-based payments777,624Net operating loss carryovers87,193Total deferred tax assets$865,573Deferred tax liabilities:Patent application costs$6,668Depreciation65Total deferred tax liabilities$6,733Total deferred tax assets$865,573Total deferred tax liabilities(6,733)Valuation allowance(858,840)Net deferred tax asset (liability)$-  NOTE 9  COMMITMENTS  In June 2007, the Company signed an agreement with a consultant to arrange financing for the Company.  If successful, the Company will pay between 10% and 17% of the proceeds to the consultant.  If the Company does not accept a financing transaction arranged by the consultant, then the Company may have to pay $5,000 per month for services under the agreement up to $60,000.  In February 2007, a vendor obtained a $16,166 default judgment against the Company for an unpaid invoice.  The judgment provides for interest at an annual rate of 6.36%.  At June 30, 2008, the Company owed $17,557 on the judgment and the amount has been included in accounts payable.


11


LIPIDVIRO TECH, INC. AND SUBSIDIARY (A Development Stage Company) NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 10 - SUBSEQUENT EVENTS  On April 2, 2008, our Board of Directors and three individuals who collectively own approximately 55.9% of our issued and outstanding shares of common stock voted:  · to effect a reverse split of our issued and outstanding shares of common stock in the ratio of one-for-14, with appropriate adjustments in our additional paid-in capital and stated capital accounts and with all fractional shares to be rounded up to the nearest whole share;  · to adopt, approve and ratify the sale of the Technology; and  · to transfer all of its shares of its wholly-owned subsidiary, LipidViro Tech, Inc., a Utah corporation, to Benedente Holdings, LLC, a Wyoming limited liability company, in consideration of Benedentes agreement to use its best efforts to negotiate the settlement of the Companys outstanding liabilities.  On July 18, 2008, which is subsequent to the period covered by this Report, we filed with the Securities and Exchange Commission a Definitive Information Statement with respect to each of these matters.  We expect to effectuate each of these transactions on or about August 21, 2008.


12


Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.  Forward-looking Statements  Statements made in this Quarterly Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and our business, including, without limitation, (i) our ability to raise capital, and (ii) statements preceded by, followed by or that include the words may, would, could, should, expects, projects, anticipates, believes, estimates, plans, intends, targets or similar expressions.  Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, general economic or industry conditions, nationally and/or in the communities in which we may conduct business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, our ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting our current or potential business and related matters.  Accordingly, results actually achieved may differ materially from expected results in these statements.  Forward-looking statements speak only as of the date they are made.  We do not undertake, and specifically disclaim, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.  Plan of Operation  Disposition of the Technology.  Due to our lack of funding to further our business plan, on January 3, 2008, our wholly-owned subsidiary, LipidViro Tech, Inc., a Utah corporation (LipidViro Utah) entered into an Option Agreement by which it granted to AcquiSci, Inc., a New Jersey corporation the option to purchase certain technology owned by LipidViro Utah, which comprises substantially all of its assets (the Technology).  AcquiSci has exercised its option and we expect that the closing of the sale of the Technology will take place in the third quarter of 2008, subject to compliance with applicable federal and state laws and regulations.  Following the completion of the Technology sale, we will no longer be engaged in the biotechnology industry.  Our plan of operation for the next 12 months is to: (i) consider guidelines of industries in which we may have an interest;(ii) adopt a business plan regarding engaging in the business of any selected industry; and (iii) to commence such operations through funding and/or the acquisition of a going concern engaged in any industry selected.  During the next 12 months, our only foreseeable cash requirements will relate to maintaining our good standing; the payment of our Securities and Exchange Commission and Exchange Act reporting filing expenses, including associated legal and accounting fees; costs incident to reviewing or investigating any potential business venture; and maintaining our good standing as a corporation in our state of organization.  We anticipate that these funds will be provided to us in the form of loans from Jenson Services.  There are no written agreements requiring Jenson Services to provide these cash resources; and to the extent funds are provided, such funds will bear no interest (though an interest expense of 10% has been imputed on funds advanced) and will be due on demand.  As of the date of this Quarterly Report, we have not actively begun to seek any business or acquisition candidate.  Results of Operations  During the quarters ended June 30, 2008, and 2007, we had losses of $108,801 and $304,830, respectively.  During the six months ended June 30, 2008, and 2007, we had losses of $219,387 and $808,450, respectively.  Liquidity  We have $25 in current cash resources.  During the next 12 months, our only foreseeable cash requirements will relate to maintaining our good standing in the State of Nevada.  We do not have any cash reserves to pay for our administrative expenses for the next 12 months.  In the event


13


that additional funding is required in order to keep us in good standing, we may attempt to raise such funding through loans or through additional sales of our common stock.    Item 3.  Quantitative and Qualitative Disclosures About Market Risk.  Not required.  Item 4T.  Controls and Procedures.  Evaluation of disclosure controls and procedures  Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q.  In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.  In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.  The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Based on that evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2008, our disclosure controls and procedures were, subject to the limitations noted above, effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules, regulations and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.  Changes in internal control over financial reporting  Our management, with the participation of the chief executive officer and chief financial officer, has concluded there were no significant changes in our internal controls over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.  PART II - OTHER INFORMATION   Item 1. Legal Proceedings.  In February 2007, Friedrich and Dimmock, Inc., a vendor, obtained a $16,166 default judgment against the Company for an unpaid invoice.  The judgment provides for interest at an annual rate of 6.36%.  At June 30, 2008, the Company owed $17,557 on the judgment and the amount has been included in accounts payable.  Item 1A.  Risk Factors.  Not required.   Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.  None; not applicable.   Item 3. Defaults Upon Senior Securities.  None; not applicable.


14


Item 4. Submission of Matters to a Vote of Security Holders.  On April 2, 2008, our Board of Directors and three individuals who collectively own approximately 55.9% of our issued and outstanding shares of common stock voted:  · to effect a reverse split of our issued and outstanding shares of common stock in the ratio of one-for-14, with appropriate adjustments in our additional paid-in capital and stated capital accounts and with all fractional shares to be rounded up to the nearest whole share;  · to adopt, approve and ratify the sale of the Technology; and  · to transfer all of its shares of its wholly-owned subsidiary, LipidViro Tech, Inc., a Utah corporation, to Benedente Holdings, LLC, a Wyoming limited liability company, in consideration of Benedentes agreement to use its best efforts to negotiate the settlement of the Companys outstanding liabilities.  On July 18, 2008, which is subsequent to the period covered by this Report, we filed with the Securities and Exchange Commission a Definitive Information Statement with respect to each of these matters.  We expect to effectuate each of these transactions on or about August 21, 2008.    Item 5. Other Information.  None; not applicable.  Item 6. Exhibits.   Exhibit No.                       Identification of Exhibit  31

32Certification of Kenneth Hamik Pursuant to Section 302 of the Sarbanes-Oxley Act.

Certification of Kenneth Hamik Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act.    SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized  LIPIDVIRO TECH, INC.  Date:August14 , 2008By:/s/Kenneth P. HamikKenneth P. Hamik, President, Chief Executive Officer and DirectorDate:August 14, 2008By:/s/Steven KeyserSteven Keyser, Director


15